Home > Boards > US Listed > Biotechs > Aurinia Pharmaceuticals Inc (AUPH)

TheFly.comPortfolio Alerts

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
lidopete Member Profile
 
Followed By 0
Posts 552
Boards Moderated 0
Alias Born 07/16/06
160x600 placeholder
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/22/2021 4:31:38 PM
Amended Current Report Filing (8-k/a) Edgar (US Regulatory) - 9/17/2021 4:04:43 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/16/2021 5:02:32 PM
Aurinia Pharmaceuticals to Present at Upcoming September Investor Conferences Business Wire - 9/15/2021 1:11:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/14/2021 6:17:15 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/14/2021 5:12:58 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/14/2021 5:11:39 PM
Aurinia Pharmaceuticals to Participate in H.C. Wainwright 23rd Annual Global Investment Conference Business Wire - 9/10/2021 1:30:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/8/2021 4:05:19 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/8/2021 4:04:21 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/27/2021 4:16:47 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/26/2021 4:16:49 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/17/2021 4:07:54 PM
Aurinia Acquires Novel Pipeline Assets Targeting Autoimmune and Kidney-related Diseases Business Wire - 8/17/2021 6:05:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/10/2021 4:09:58 PM
Aurinia Pharmaceuticals to Present at the BTIG Virtual Biotech Conference Business Wire - 8/9/2021 7:55:00 AM
SCWorx, Aurinia Pharmaceuticals leads healthcare gainers; Dicerna Pharmaceuticals, iCAD among major losers Seeking Alpha - 8/6/2021 11:02:32 AM
Aurinia Pharma extends gains following robust Q2 top-line growth Seeking Alpha - 8/6/2021 6:08:45 AM
Aurinia Pharma EPS misses by $0.01, beats on revenue Seeking Alpha - 8/5/2021 4:16:06 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/5/2021 4:14:46 PM
Aurinia Reports Second Quarter and Six Months 2021 Financial Results and Recent Operational Highlights Business Wire - 8/5/2021 4:05:00 PM
Eyes will be on Aurinia's lupus drug Lupkynis during Q2 2021 earnings today Seeking Alpha - 8/5/2021 11:46:57 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/29/2021 4:11:23 PM
Aurinia Pharmaceuticals to Release Second Quarter 2021 Financial Results on August 5, 2021 Business Wire - 7/26/2021 6:05:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/19/2021 6:02:19 AM
lidopete   Thursday, 05/20/21 05:37:52 PM
Re: None
Post # of 13638 

TheFly.com

Portfolio Alerts
Click the Portfolio Name or Symbol to see the research on thefly.com
Main Portfolio matches: AUPH.

TODAY, MAY 20, 2021
AUPH
16:08
Hot Stocks
Aurinia to present 'supportive' AURORA 2 study interim analysis
Aurinia Pharmaceuticals announced that a supportive interim analysis of its AURORA 2 continuation study will be presented at the upcoming European Alliance of Associations for Rheumatology 2021 Congress June 2-5, 2021. Subjects who completed one year of treatment in Aurinia's Phase 3 AURORA study were eligible to enroll in the two-year, blinded, controlled continuation study. The interim analysis to be presented at EULAR evaluated subjects with up to two years of total treatment: one year from AURORA 1 and up to one year in AURORA 2. Previously reported results from AURORA 1 and the Phase 2 AURA-LV study showed that compared with mycophenolate mofetil and low-dose steroids alone, the addition of voclosporin significantly increased the renal response rate and reduced proteinuria, as measured by urine protein creatinine ratio, in subjects with lupus nephritis at approximately one year of treatment. The interim analysis of AURORA 2 showed that subjects in the LUPKYNIS treatment arm sustained meaningful reductions in proteinuria, with no change in mean estimated glomerular filtration rate at 104 weeks of treatment. "Following the enhanced renal response rates achieved in AURORA 1, these additional data show that LUPKYNIS also provides the ability to sustain positive outcomes over time," said Amit Saxena, M.D., Assistant Professor at the Department of Medicine at NYU Langone Medical Center. "The strong and growing pool of data available on LUPKYNIS clearly demonstrates the clinical value and safety of this therapy for a patient population that has historically been challenged with a lack of effective treatment options."

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences